Skip to main content
Top
Published in: Acta Diabetologica 1/2015

01-02-2015 | Original Article

Oxidative stress predicts progression of peripheral and cardiac autonomic nerve dysfunction over 6 years in diabetic patients

Authors: Dan Ziegler, Stefanie Buchholz, Christoph Sohr, Jaffar Nourooz-Zadeh, Michael Roden

Published in: Acta Diabetologica | Issue 1/2015

Login to get access

Abstract

Oxidative stress is implicated in the pathogenesis of experimental diabetic neuropathy, but prospective studies in diabetic patients are lacking. We aimed to evaluate whether the plasma levels of various biomarkers of oxidative stress predict the progression of diabetic neuropathy and mortality over 6 years. We followed 89 diabetic patients aged 54 ± 14 years (59 % with polyneuropathy), 72 of whom underwent nerve function reassessment after 6.2 ± 0.8 years, whereas 17 died after 4.2 ± 1.0 years. Plasma markers of oxidative stress at baseline included superoxide anion, hypochlorous acid, peroxynitrite, 8-iso-prostaglandin F2α, vitamin E/lipid ratio, and vitamin C. Neuropathy was assessed by symptoms and deficits, motor and sensory nerve conduction velocity (MNCV, SNCV), vibration perception thresholds (VPT), thermal detection thresholds, and heart rate variability (HRV). Despite a reduction in HbA1c by 1.4 ± 1.6 % (p < 0.001), median SNCV, sural SNCV, peroneal MNCV, malleolar VPT, and warm TDT deteriorated after 6 years (all p < 0.05). In multivariate models, increased superoxide generation was associated with a decline in median SNCV (β = −0.997; p = 0.036) and deterioration in HRV at rest (OR 1.63 [95 % CI 1.09–2.44]; p = 0.017) over 6 years. Low vitamin E/lipid ratio tended to predict a decrease in peroneal MNCV (β = 0.781; p = 0.057) and an increase in malleolar VPT (β = −0.725; p = 0.077). Plasma superoxide generation was associated with an increased risk of mortality (HR 23.2 [95 % CI 1.05–513]; p = 0.047). In conclusion, increased plasma superoxide generation predicted the decline in sensory and cardiac autonomic nerve function and mortality over 6 years in diabetic patients, but larger studies are required for confirmation.
Literature
1.
go back to reference Boulton AJM, Vinik AI, Arezzo JC et al (2005) Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28:956–962PubMedCrossRef Boulton AJM, Vinik AI, Arezzo JC et al (2005) Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 28:956–962PubMedCrossRef
2.
go back to reference Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A; KORA Study Group (2008) Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 31:464–469CrossRef Ziegler D, Rathmann W, Dickhaus T, Meisinger C, Mielck A; KORA Study Group (2008) Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 31:464–469CrossRef
3.
go back to reference Hsu WC, Chiu SY, Yen AM et al (2012) Somatic neuropathy is an independent predictor of all- and diabetes-related mortality in type 2 diabetic patients: a population-based 5-year follow-up study (KCIS No. 29). Eur J Neurol 19:1192–1198PubMedCrossRef Hsu WC, Chiu SY, Yen AM et al (2012) Somatic neuropathy is an independent predictor of all- and diabetes-related mortality in type 2 diabetic patients: a population-based 5-year follow-up study (KCIS No. 29). Eur J Neurol 19:1192–1198PubMedCrossRef
5.
go back to reference Vincent AM, Callaghan BC, Smith AL, Feldman EL (2011) Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol 7:573–583PubMedCrossRef Vincent AM, Callaghan BC, Smith AL, Feldman EL (2011) Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol 7:573–583PubMedCrossRef
6.
go back to reference Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820PubMedCrossRef Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820PubMedCrossRef
7.
go back to reference El Boghdady NA, Badr GA (2012) Evaluation of oxidative stress markers and vascular risk factors in patients with diabetic peripheral neuropathy. Cell Biochem Funct 30:328–334PubMedCrossRef El Boghdady NA, Badr GA (2012) Evaluation of oxidative stress markers and vascular risk factors in patients with diabetic peripheral neuropathy. Cell Biochem Funct 30:328–334PubMedCrossRef
8.
go back to reference Uzar E, Tamam Y, Evliyaoglu O et al (2012) Serum prolidase activity and oxidative status in patients with diabetic neuropathy. Neurol Sci 33:875–880PubMedCrossRef Uzar E, Tamam Y, Evliyaoglu O et al (2012) Serum prolidase activity and oxidative status in patients with diabetic neuropathy. Neurol Sci 33:875–880PubMedCrossRef
9.
go back to reference Ozkul A, Ayhan M, Yenisey C, Akyol A, Guney E, Ergin FA (2010) The role of oxidative stress and endothelial injury in diabetic neuropathy and neuropathic pain. Neuro Endocrinol Lett 31:261–264PubMed Ozkul A, Ayhan M, Yenisey C, Akyol A, Guney E, Ergin FA (2010) The role of oxidative stress and endothelial injury in diabetic neuropathy and neuropathic pain. Neuro Endocrinol Lett 31:261–264PubMed
10.
go back to reference Hoeldtke RD, Bryner KD, McNeill DR, Warehime SS, Van Dyke K, Hobbs G (2003) Oxidative stress and insulin requirements in patients with recent-onset type 1 diabetes. J Clin Endocrinol Metab 88:1624–1628PubMedCrossRef Hoeldtke RD, Bryner KD, McNeill DR, Warehime SS, Van Dyke K, Hobbs G (2003) Oxidative stress and insulin requirements in patients with recent-onset type 1 diabetes. J Clin Endocrinol Metab 88:1624–1628PubMedCrossRef
11.
go back to reference Hoeldtke RD, Bryner KD, Hoeldtke ME et al (2006) Sympathetic sudomotor disturbance in early type 1 diabetes mellitus is linked to lipid peroxidation. Metabolism 55:1524–1531PubMedCrossRef Hoeldtke RD, Bryner KD, Hoeldtke ME et al (2006) Sympathetic sudomotor disturbance in early type 1 diabetes mellitus is linked to lipid peroxidation. Metabolism 55:1524–1531PubMedCrossRef
12.
go back to reference Hoeldtke RD, Bryner KD, Corum LL, Hobbs GR, Van Dyke K (2009) Lipid peroxidation in early type 1 diabetes mellitus is unassociated with oxidative damage to DNA. Metabolism 58:731–734PubMedCrossRef Hoeldtke RD, Bryner KD, Corum LL, Hobbs GR, Van Dyke K (2009) Lipid peroxidation in early type 1 diabetes mellitus is unassociated with oxidative damage to DNA. Metabolism 58:731–734PubMedCrossRef
13.
go back to reference Hoeldtke RD, Bryner KD, VanDyke K (2011) Oxidative stress and autonomic nerve function in early type 1 diabetes. Clin Auton Res 21:19–28PubMedCrossRef Hoeldtke RD, Bryner KD, VanDyke K (2011) Oxidative stress and autonomic nerve function in early type 1 diabetes. Clin Auton Res 21:19–28PubMedCrossRef
14.
go back to reference Ziegler D, Sohr CGH, Nourooz-Zadeh J (2004) Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and autonomic neuropathy. Diabetes Care 27:2178–2183PubMedCrossRef Ziegler D, Sohr CGH, Nourooz-Zadeh J (2004) Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and autonomic neuropathy. Diabetes Care 27:2178–2183PubMedCrossRef
15.
go back to reference Ziegler D, Mayer P, Mühlen H, Gries FA (1991) The natural history of somatosensory and autonomic nerve dysfunction in relation to glycaemic control during the first 5 years after diagnosis of Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 34:822–829PubMedCrossRef Ziegler D, Mayer P, Mühlen H, Gries FA (1991) The natural history of somatosensory and autonomic nerve dysfunction in relation to glycaemic control during the first 5 years after diagnosis of Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 34:822–829PubMedCrossRef
16.
go back to reference Dyck PJ, Davies JL, Litchy WJ, O’Brien PC (1997) Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 49:229–239PubMedCrossRef Dyck PJ, Davies JL, Litchy WJ, O’Brien PC (1997) Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort. Neurology 49:229–239PubMedCrossRef
17.
go back to reference Young MJ, Boulton AJM, Macleod AF, Williams DRR, Sonksen PH (1993) A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 36:150–154PubMedCrossRef Young MJ, Boulton AJM, Macleod AF, Williams DRR, Sonksen PH (1993) A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 36:150–154PubMedCrossRef
18.
go back to reference Ziegler D, Laux G, Dannehl K et al (1992) Assessment of cardiovascular autonomic function: age-related normal ranges and reproducibility of spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses. Diabet Med 9:166–175PubMedCrossRef Ziegler D, Laux G, Dannehl K et al (1992) Assessment of cardiovascular autonomic function: age-related normal ranges and reproducibility of spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses. Diabet Med 9:166–175PubMedCrossRef
19.
go back to reference Ziegler D, Dannehl K, Mühlen H, Spüler M, Gries FA (1992) Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses at various stages of diabetic neuropathy. Diabet Med 9:806–814PubMedCrossRef Ziegler D, Dannehl K, Mühlen H, Spüler M, Gries FA (1992) Prevalence of cardiovascular autonomic dysfunction assessed by spectral analysis, vector analysis, and standard tests of heart rate variation and blood pressure responses at various stages of diabetic neuropathy. Diabet Med 9:806–814PubMedCrossRef
20.
go back to reference Nourooz-Zadeh J, Gopaul NK, Barrow S, Mallet AI, Anggard EE (1995) Analysis of F2-isoprostanes as indicators of non-enzymatic lipid peroxidation in vivo by gas chromatography-mass spectrometry: development of a solid-phase extraction procedure. J Chromatogr B Biomed Appl 667:199–208PubMedCrossRef Nourooz-Zadeh J, Gopaul NK, Barrow S, Mallet AI, Anggard EE (1995) Analysis of F2-isoprostanes as indicators of non-enzymatic lipid peroxidation in vivo by gas chromatography-mass spectrometry: development of a solid-phase extraction procedure. J Chromatogr B Biomed Appl 667:199–208PubMedCrossRef
21.
go back to reference Nourooz-Zadeh J (1999) Gas chromatography-mass spectrometry assay for measurement of plasma isoprostanes. Methods Enzymol 300:13–17PubMedCrossRef Nourooz-Zadeh J (1999) Gas chromatography-mass spectrometry assay for measurement of plasma isoprostanes. Methods Enzymol 300:13–17PubMedCrossRef
22.
go back to reference Nourooz-Zadeh J, Rahimi A, Tajaddini-Sarmadi J et al (1997) Relationships between plasma measures of oxidative stress and metabolic control in NIDDM. Diabetologia 40:647–653PubMedCrossRef Nourooz-Zadeh J, Rahimi A, Tajaddini-Sarmadi J et al (1997) Relationships between plasma measures of oxidative stress and metabolic control in NIDDM. Diabetologia 40:647–653PubMedCrossRef
23.
go back to reference Obrosova IG, Minchenko AG, Marinescu V et al (2001) Antioxidants attenuate early upregulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Diabetologia 44:1102–1110PubMedCrossRef Obrosova IG, Minchenko AG, Marinescu V et al (2001) Antioxidants attenuate early upregulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Diabetologia 44:1102–1110PubMedCrossRef
24.
go back to reference Knight J, Ganderton M, Hothersall J, Zitouni K (2002) Nourooz-Zadeh J (2002) The ABEL® peroxynitrite antioxidant test with pholasin® measures the antioxidant capacity of plasma to protect against peroxyl radical attack. In: Stanley PE, Kricka LJ (eds) Bioluminescence chemiluminescence: progress and current applications. World Scientific, London, pp 256–260 Knight J, Ganderton M, Hothersall J, Zitouni K (2002) Nourooz-Zadeh J (2002) The ABEL® peroxynitrite antioxidant test with pholasin® measures the antioxidant capacity of plasma to protect against peroxyl radical attack. In: Stanley PE, Kricka LJ (eds) Bioluminescence chemiluminescence: progress and current applications. World Scientific, London, pp 256–260
25.
go back to reference Low PA, Nickander KK (1991) Oxygen free radical effects in sciatic nerve in experimental diabetes. Diabetes 40:873–877PubMedCrossRef Low PA, Nickander KK (1991) Oxygen free radical effects in sciatic nerve in experimental diabetes. Diabetes 40:873–877PubMedCrossRef
26.
go back to reference Coppey LJ, Gellett JS, Davidson EP, Yorek MA (2003) Preventing superoxide formation in epineurial arterioles of the sciatic nerve from diabetic rats restores endothelium-dependent vasodilation. Free Radic Res 37:33–40PubMedCrossRef Coppey LJ, Gellett JS, Davidson EP, Yorek MA (2003) Preventing superoxide formation in epineurial arterioles of the sciatic nerve from diabetic rats restores endothelium-dependent vasodilation. Free Radic Res 37:33–40PubMedCrossRef
27.
go back to reference Zherebitskaya E, Akude E, Smith DR, Fernyhough P (2009) Development of selective axonopathy in adult sensory neurons isolated from diabetic rats: role of glucose-induced oxidative stress. Diabetes 58:1356–1364PubMedCentralPubMedCrossRef Zherebitskaya E, Akude E, Smith DR, Fernyhough P (2009) Development of selective axonopathy in adult sensory neurons isolated from diabetic rats: role of glucose-induced oxidative stress. Diabetes 58:1356–1364PubMedCentralPubMedCrossRef
29.
go back to reference Nickander KK, McPhee BR, Low PA, Tritschler H (1996) Alpha-lipoic acid: antioxidant potency against lipid peroxidation of neural tissues in vitro and implications for diabetic neuropathy. Free Radic Biol Med 21:631–639PubMedCrossRef Nickander KK, McPhee BR, Low PA, Tritschler H (1996) Alpha-lipoic acid: antioxidant potency against lipid peroxidation of neural tissues in vitro and implications for diabetic neuropathy. Free Radic Biol Med 21:631–639PubMedCrossRef
30.
go back to reference Sayın R, Aslan M, Kucukoglu ME et al (2013) Serum prolidase enzyme activity and oxidative stress levels in patients with diabetic neuropathy. Endocrine 2013 Dec 18 [Epub ahead of print] Sayın R, Aslan M, Kucukoglu ME et al (2013) Serum prolidase enzyme activity and oxidative stress levels in patients with diabetic neuropathy. Endocrine 2013 Dec 18 [Epub ahead of print]
31.
go back to reference Kasznicki J, Kosmalski M, Sliwinska A et al (2012) Evaluation of oxidative stress markers in pathogenesis of diabetic neuropathy. Mol Biol Rep 39:8669–8678PubMedCentralPubMedCrossRef Kasznicki J, Kosmalski M, Sliwinska A et al (2012) Evaluation of oxidative stress markers in pathogenesis of diabetic neuropathy. Mol Biol Rep 39:8669–8678PubMedCentralPubMedCrossRef
32.
go back to reference Acharya JD, Pande AJ, Joshi SM, Yajnik CS, Ghaskadbi SS (2014) Treatment of hyperglycemia in newly diagnosed diabetic patients is associated with a reduction in oxidative stress and improvement in β-cell function. Diabetes Metab Res Rev 2014 Jan 24. doi: 10.1002/dmrr.2526 Acharya JD, Pande AJ, Joshi SM, Yajnik CS, Ghaskadbi SS (2014) Treatment of hyperglycemia in newly diagnosed diabetic patients is associated with a reduction in oxidative stress and improvement in β-cell function. Diabetes Metab Res Rev 2014 Jan 24. doi: 10.​1002/​dmrr.​2526
33.
go back to reference van Dam PS, Bravenboer B, van Asbeck BS, van Oirschot JF, Marx JJ, Gispen WH (1996) Effects of insulin treatment on endoneurial and systemic oxidative stress in relation to nerve conduction in streptozotocin-diabetic rats. Eur J Clin Invest 26:1143–1149PubMedCrossRef van Dam PS, Bravenboer B, van Asbeck BS, van Oirschot JF, Marx JJ, Gispen WH (1996) Effects of insulin treatment on endoneurial and systemic oxidative stress in relation to nerve conduction in streptozotocin-diabetic rats. Eur J Clin Invest 26:1143–1149PubMedCrossRef
34.
go back to reference Ziegler D, Low PA, Litchy WJ et al (2011) Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 34:2054–2060PubMedCentralPubMedCrossRef Ziegler D, Low PA, Litchy WJ et al (2011) Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 34:2054–2060PubMedCentralPubMedCrossRef
35.
go back to reference Pop-Busui R, Stevens MJ, Raffel DM et al (2013) Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial. Diabetologia 56:1835–1844PubMedCentralPubMedCrossRef Pop-Busui R, Stevens MJ, Raffel DM et al (2013) Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial. Diabetologia 56:1835–1844PubMedCentralPubMedCrossRef
Metadata
Title
Oxidative stress predicts progression of peripheral and cardiac autonomic nerve dysfunction over 6 years in diabetic patients
Authors
Dan Ziegler
Stefanie Buchholz
Christoph Sohr
Jaffar Nourooz-Zadeh
Michael Roden
Publication date
01-02-2015
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 1/2015
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-014-0601-3

Other articles of this Issue 1/2015

Acta Diabetologica 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.